| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Ozanezumab
CAS:1310680-64-8
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Ozanezumab(DHK06701)
CAS:1310680-64-8
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Ozanezumab
CAS:1310680-64-8
Purity:95% Package:1mg;5mg
|
|
| | Ozanezumab Basic information |
| Product Name: | Ozanezumab | | Synonyms: | Ozanezumab;Research Grade Ozanezumab(DHK06701);Research Grade Ozanezumab | | CAS: | 1310680-64-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ozanezumab Structure]() |
| | Ozanezumab Chemical Properties |
| | Ozanezumab Usage And Synthesis |
| Uses | Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research[1]. | | References | [1] Meininger V, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar;16(3):208-216. DOI:10.1016/S1474-4422(16)30399-4 |
| | Ozanezumab Preparation Products And Raw materials |
|